Table 1.
Clinical and demographic statistics of patients enrolled in this study
| Benign (n=13) |
EOC (n=27) |
EOC with survival outcome (n=20) | TCGA (n=519) |
|
| Race | ||||
| White | 8 | 21 | 16 | 456 |
| Non-white | 5 | 6 | 4 | 63 |
| Age | ||||
| Range (years) | 38–71 | 31–87 | 31–86 | 26–87 |
| Mean (years) | 51 | 67 | 63 | 60 |
| SD (years) | 13 | 12 | 13 | 12 |
| Stage | ||||
| IIB | – | 2 | 2 | 0 |
| IIIA | – | 0 | 0 | 8 |
| IIIB | – | 4 | 4 | 23 |
| IIIC | – | 19 | 12 | 404 |
| IV | – | 2 | 2 | 84 |
| Histopathology | ||||
| High-grade serous | – | 27 | 20 | 500 |
| Low-grade serous | – | 0 | 0 | 19 |
27 patients with malignant and 13 with benign were recruited for this study. Of the 27 EOC subjects, 20 had sufficient clinical to perform survival analysis. Finally, we used a validation cohort of 519 cases of EOC from the TCGA ovarian cancer database. The summary statistics on race, age at diagnosis and tumortumor pathological stage are in this table.
EOC, epithelial ovarian cancer; TCGA, The Cancer Genome Atlas.